European Journal of Biomedical and Pharmaceutical Sciences

A PROSPECTIVE STUDY ON EVALUATION OF EFFICACY AND SAFETY OF VILAZODONE IN DEPRESSION

Jisha Vijayan*, Jereena E., Anil Babu and Anagha R.

ABSTRACT

Background and Objectives: Vilazodone a novel Serotonin Reuptake Inhibitor and 5-HT1A.Partial Agonist that is recently developed for the treatment of Major Depressive Disorder. The main objective of study to evaluate the efficacy and safety of vilazodone in depression. Methods: This is a prospective, observational, 9 month study conducted on department of psychiatry in a 500 bed tertiary care teaching hospital. The study population includes 30 subjects aged between 18-60 years with major depressive disorder (DSM-IV criteria). Vilazodone was titrated from 10 mg to 20 mg and efficacy assessed by mean change from baseline to week 4 on Hamilton Depression Rating Scale (HAMD), Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression-Severity scale (CGI-S) and Improvement scale (CGI-I). Data were analysed using statistical package for social science version 20.Results and Discussion: The mean changes in HAMD-17 total scores, MADRS total score, CGI-S score and CGI-I score from baseline to week 4 were significantly greater in Vilazodone treated patients. Improvement in Hamilton Depression Rating Score, Montgomery-Asberg Depression Rating Score, Clinical Global Impression- Severity score and Improvement score were noted in 1 week, the earliest time point measured and persist till week 4 indicating reduction in depression symptomatology. Higher response and remission rate were shown by vilazodone treated patient on HAMD-17 and MADRS. Most common adverse events noted include diarrhea .Conclusion: Vilazodone is effective for treatment of Major Depressive Disorder in adults with symptom relief starting at 1 week and is well tolerated at dose of 20 mg/day.

Keywords: Vilazodone; Safety; Efficacy; Major Depressive Disorder.